<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947531</url>
  </required_header>
  <id_info>
    <org_study_id>EBE-RU-051201</org_study_id>
    <nct_id>NCT00947531</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia</brief_title>
  <acronym>VascDem</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ever Neuro Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>acromion GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Geny Research Corp.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ever Neuro Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial was performed to assess the clinical efficacy and safety of two 4 week
      treatment courses of daily intravenous administration of Cerebrolysin (20mL [milliliter] IV
      [intravenous] per day). The study was performed as prospective, randomised, double-blind,
      placebo-controlled, parallel group, multicentre study with 2 study groups.

      Group 1: 20 mL Cerebrolysin and 100 mg (milligram) acetylsalicylic acid Group 2: Placebo
      (0.9% NaCl [sodium chloride]) and 100 mg acetylsalicylic acid The study drug was given once
      daily by intravenous infusion (20ml in 250ml saline solution) for 4 weeks on five consecutive
      days per week. This treatment regimen was repeated after a two-month treatment-free interval.
      Acetylsalicylic acid was given orally, once daily throughout the study duration of 24 weeks.

      Altogether five clinical evaluation visits at Baseline (day 0) and at week 4, 12, 16, and 24
      were necessary.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24</measure>
    <time_frame>baseline and week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CIBIC+ (Clinicians Interview-based Impression of Change) Score at Week 24</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Experiences, Vital Signs, Physical and Neurological Examinations, Laboratory Tests (Hematology, Clinical Chemistry, Urinalysis ), ECG (Electrocardiogram)</measure>
    <time_frame>Baseline, week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ADAS-COG+ (Alzheimer's Disease Assessment Scale Cognitive Subpart)</measure>
    <time_frame>week 4, 12, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAS-COG+ Response</measure>
    <time_frame>week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Original ADAS-COG</measure>
    <time_frame>week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIC+ Sscore</measure>
    <time_frame>week 4, 12, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIC+ Response</measure>
    <time_frame>week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CIBIS+ (Clinicians Interview-Based Impression of Severity)</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MMSE (Mini-Mental State Examination) Score</measure>
    <time_frame>week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale)</measure>
    <time_frame>week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trail-making Test</measure>
    <time_frame>week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clock-drawing Test</measure>
    <time_frame>week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Response, i.e. Response in ADAS-COG+ and CIBIC+</measure>
    <time_frame>week 4, 12, 16, 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Vascular Dementia</condition>
  <arm_group>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin</intervention_name>
    <arm_group_label>Cerebrolysin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Saline Solution</intervention_name>
    <arm_group_label>0.9% Saline Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or post-menopausal women between 50 and 85 years

          -  Clinical diagnosis of vascular dementia according to NINDS-AIREN criteria

          -  CT or MRI results compatible with clinical diagnosis

          -  MMSE score between 10 and 24, both inclusive

          -  Modified Hachinski Ischemic Score &gt;4

          -  Hamilton Depression Scale score of less than or equal to 15

          -  Adequate visual and auditory acuity to allow neuropsychological testing

          -  Informed consent given by the patient and/or the next-of-kin

        Exclusion Criteria:

          -  Gastric ulcer associated with intolerance of acetylsalicylic acid treatment

          -  Severe psychotic features, schizophrenia, depression, agitation or behavioral problems
             within the last three months that could lead to difficulty complying with the protocol

          -  Any severe systemic illness or unstable medical condition that could lead to
             difficulty complying with the protocol or significantly limits life span.

          -  Patients who in the investigator's opinion, would not comply with study procedures

          -  Any significant neurological disease other than vascular dementia, such as Parkinson's
             disease, epilepsy, Huntington's disease, normal pressure hydrocephalus, brain tumor,
             progressive supranuclear palsy, seizure disorder, subdural hematoma, or multiple
             sclerosis

          -  History of alcohol or substance abuse or dependence within the past two years

          -  Patients with a history of systemic cancer within the past two years

          -  Severe congestive heart failure or malignant, uncontrollable hypertension

          -  Participation in a clinical trial with an investigational drug in the past four weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Novak, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EBEWE Neuro Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chita State Medical Academy/Regional Psychiatric Hospital No. 2</name>
      <address>
        <city>Chita</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chita State Medical Academy/Veterans Hospital</name>
      <address>
        <city>Chita</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irkutsk State Institute of Postgraduate Education/Regional Clinical Hospital</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University/Municipal Clinical Hospital No. 6</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University/Republican Clinical Hospital</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk Medical University/Kursk Regional Clinical Hospital</name>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. M. Sechenov Moscow Medical Academy</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Center of RAMS/Psychiatric Clinical Hospital No. 15</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Center of RAMS</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Medical Academy of Postgraduate Education/S. P. Botkin Municipal Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian State Medical University/N. I. Pirogov Municipal Clinical Hospital No. 1</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Neurology of RAMS</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Clinical Hospital No. 5</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N. A. Semashko Nizhniy Novgorod Regional Clinical Hospital</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Municipal Hospital</name>
      <address>
        <city>Reutov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov Regional Psychiatric Hospital of Snt. Sofia</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. P. Pavlov St. Petersburg State Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. M. Kirkov Medical Military Academy of the Ministry of Defense of RF</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>V. M. Bekhterev St. Petersburg Scientific Research Psychoneurological Institute</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bashkirian State Medical University/Emergency Medical Care Hospital</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl State Medical Academy/Yaroslavl Clinical Hospital No. 8</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <results_first_submitted>April 20, 2009</results_first_submitted>
  <results_first_submitted_qc>June 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2009</results_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Philipp Novak, PhD</name_title>
    <organization>EBEWE Neuro Pharma</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of recruitment period: 24-Oct-2006 - 02-Feb-2007 Type of location: Hospitals, Medical Universities, Medical Military Academy, Research Institutes</recruitment_details>
      <pre_assignment_details>Patients were excluded from the trial before assignment to a group when not all inclusion criteria were met or when exclusion criteria were applicable.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cerebrolysin</title>
        </group>
        <group group_id="P2">
          <title>0.9% Saline Solution</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="121"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cerebrolysin</title>
        </group>
        <group group_id="B2">
          <title>0.9% Saline Solution</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="121"/>
            <count group_id="B3" value="242"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="8.0"/>
                    <measurement group_id="B2" value="67.6" spread="8.0"/>
                    <measurement group_id="B3" value="67.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24</title>
        <description>The ADAS-COG+ is a psychometric instrument used to evaluate memory, attention, reasoning, language, orientation and praxis. The score ranges from 0 to 85 with 85 being the worst score. A negative change indicates cognitive improvement.</description>
        <time_frame>baseline and week 24</time_frame>
        <population>The primary and confirmatory analysis is based on the ITT analysis set. The LOCF method is applied to account for missing data. The ITT analysis set consists of all randomized patients, who received at least one dose of study medication and had a baseline and at least one post-baseline assessment for both primary efficacy measures.</population>
        <group_list>
          <group group_id="O1">
            <title>Cerebrolysin</title>
          </group>
          <group group_id="O2">
            <title>0.9% Saline Solution</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24</title>
          <description>The ADAS-COG+ is a psychometric instrument used to evaluate memory, attention, reasoning, language, orientation and praxis. The score ranges from 0 to 85 with 85 being the worst score. A negative change indicates cognitive improvement.</description>
          <population>The primary and confirmatory analysis is based on the ITT analysis set. The LOCF method is applied to account for missing data. The ITT analysis set consists of all randomized patients, who received at least one dose of study medication and had a baseline and at least one post-baseline assessment for both primary efficacy measures.</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.60" spread="7.77"/>
                    <measurement group_id="O2" value="-4.49" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null-hypothesis stated no difference between the two treatment groups. A sample size of 103 evaluable patients per treatment group was estimated to allow for the detection of a significant group difference of 4.1 points in ADAS-cog+ weak 24 change score (standard deviation [SD] 9.0) in favor of Cerebrolysin with a power of 90% and a probability level of alpha-level 0.025 (one-sided).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>P-value obtained from the F-test statistic of Cerebrolysin versus Placebo as part of ANCOVA (analysis of covariance). No adjustment for multiple comparisons was needed. The overall significance level alpha was fixed at alpha = 0.05 (two-sided).</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>The study was designed to show significant differences in each of the two primary variables. No adjustment for multiple comparisons was needed.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.22</ci_lower_limit>
            <ci_upper_limit>-4.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CIBIC+ (Clinicians Interview-based Impression of Change) Score at Week 24</title>
        <time_frame>week 24</time_frame>
        <posting_date>09/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Experiences, Vital Signs, Physical and Neurological Examinations, Laboratory Tests (Hematology, Clinical Chemistry, Urinalysis ), ECG (Electrocardiogram)</title>
        <time_frame>Baseline, week 4, 12, 16, 24</time_frame>
        <posting_date>09/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ADAS-COG+ (Alzheimer’s Disease Assessment Scale Cognitive Subpart)</title>
        <description>The modified Alzheimer’s Disease Assessment Scale – Cognitive (ADAS-COG+) is a psychometric instrument used by a neuropsychologist that evaluates memory, attention, reasoning, language, orientation and praxis.</description>
        <time_frame>week 4, 12, 16</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADAS-COG+ Response</title>
        <description>A patient with an improvement from baseline of ≥ 4 points in the ADAS-COG+ score at a particular visit is considered to have an ADAS-COG+ response at that visit.</description>
        <time_frame>week 4, 12, 16, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Original ADAS-COG</title>
        <description>The Original Alzheimer’s Disease Assessment Scale – Cognitive (ADAS-COG) is comprised of items 1-11 of the modified ADAS-COG+.</description>
        <time_frame>week 4, 12, 16, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CIBIC+ Sscore</title>
        <description>The Clinician Interview-based Impression of Change (CIBIC+) score is assigned by an experienced physician familiar with the manifestations of dementia after interviewing the patient and the caregiver.</description>
        <time_frame>week 4, 12, 16</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CIBIC+ Response</title>
        <description>A patient with a CIBIC+ score of 1 to 3 at a particular visit is considered to have a CIBIC+ response at that visit. Patients with a score of 0, indicating that the assessment was not performed, are considered to be non-responders.</description>
        <time_frame>week 4, 12, 16, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CIBIS+ (Clinicians Interview-Based Impression of Severity)</title>
        <description>The Clinician Interview-based Impression of Disease Severity (CIBIS+) score is assigned by an experienced physician, familiar with the manifestations of dementia, after interviewing the patient and the caregiver.</description>
        <time_frame>week 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MMSE (Mini-Mental State Examination) Score</title>
        <description>The Mini-Mental State Examination (MMSE) is a frequently used screening instrument for clinical trials conducted in patients with Alzheimer’s Disease. It evaluates orientation, registration, attention and calculation, recall and language.</description>
        <time_frame>week 4, 12, 16, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale)</title>
        <description>The ADCS-ADL is a measure of functional disability. The ADCS-ADL assessment of activities of daily living is based on an interview with the caregiver.</description>
        <time_frame>week 4, 12, 16, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trail-making Test</title>
        <description>The Trail-making test is a frequently used instrument for the assessment of executive function.</description>
        <time_frame>week 4, 12, 16, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clock-drawing Test</title>
        <description>The Clock-drawing test is a frequently used screening instrument for dementia drug studies. It evaluates executive function of demented patients.</description>
        <time_frame>week 4, 12, 16, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Response, i.e. Response in ADAS-COG+ and CIBIC+</title>
        <time_frame>week 4, 12, 16, 24</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cerebrolysin</title>
        </group>
        <group group_id="E2">
          <title>0.9% Saline Solution</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Philipp Novak</name_or_title>
      <organization>Ebewe Neuro Pharma</organization>
      <phone>+43 7665 8123 ext 733</phone>
      <email>philipp.novak@ebewe-neuro.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

